DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...

Stock analysts at StockNews.com initiated coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever 0.0% of Sorrento Therapeutics shares are owned by institutional investors.

Ko­jin Ther­a­peu­tics, a start­up at­tempt­ing to de­vel­op new treat­ments us­ing pro­grammed cell death, left last month’s JP Mor­gan Health­care Con­fer­ence in a bind.

NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage ...

Germany’s Merck MRK-2.82%decrease; red down pointing triangle KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics SWTX-3.57%decrease; red down pointing ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare diseases drugmaker soaring. One of SpringWorks’ drugs, Ogsiveo ...

Update 2:15pm: Adds Merck KGaA confirmation. SpringWorks Therapeutics (NASDAQ:SWTX) soared ~40% after a report that Merck KGaA (OTCPK:MKGAF) is in advanced discussions to acquire the cancer and ...

SpringWorks Therapeutics (NASDAQ:SWTX) may be valued at about $77 a share in a possible takeover after a report earlier that Merck KGaA (OTCPK:MKGAF) is in talks for a purchase of the cancer and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...